DOXORUBICIN CARDIOTOXICITY IN PATIENTS W/ BREAST CANCER IS PREVENTED BY ICRF 187

ICRF 187 可预防乳腺癌患者的阿霉素心脏毒性

• 批准号: 3843452
• 负责人: V J FERRANS
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3843452
• 关键词: biopsy; cardiotoxin; cardiovascular disorder prevention; combination cancer therapy; cyclophosphamide; doxorubicin; drug adverse effect; female; fluorouracil; human subject; human therapy evaluation; myocardium; myocardium disorder; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology

Clinical and myocardial biopsy studies were made to evaluate the protective role of ICRF 187 in the prevention of doxorubicin-induced chronic cardiomyopathy in 150 patients with breast cancer who received chemotherapy with doxorubicin, cyclophosphamide and 5-fluorouracil, with or without ICRF 187. The study showed that ICRF provides protection against doxorubicin- induced cardiac toxicity in women with breast cancer without altering the antitumor efficacy of the regimen or adding significantly to its toxicity. Women receiving ICRF 187 were able to receive more cycles and higher cumulative doses of doxorubicin with considerably less cardiac toxicity.

通过临床和心肌活检研究来评估保护性心肌保护作用。 ICRF 187在预防多柔比星所致慢性炎症中的作用 150例接受化疗的乳腺癌患者的心肌病 联合阿霉素、环磷酰胺和5-氟尿嘧啶，联合或不联合ICRF 187.该研究表明，ICRF提供了对阿霉素的保护- 在乳腺癌女性中诱导心脏毒性，而不改变 该方案的抗肿瘤功效或显著增加其毒性。 接受ICRF 187治疗的妇女能够接受更多的周期， 多柔比星的累积剂量具有相当少的心脏毒性。